The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

NCT04776889 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Rosuvastatin 20mg
PROCEDURE: surgical castration

Sponsor

National Cancer Institute, Egypt